Samuel12_1980

Samuel12_1980

Clinical trial for EYSUVIS (KPI-121) - top line results of Phase III expected on first Q of 2020. The concern is : cash position as of September 30 was $97.6 million, compared to $170.9 million as of December 31, 2018. I do not suggest to buy\sell . Good-luck

Samuel12_1980

Added more Not for any suggestion Good-luck

Samuel12_1980

Long. Good luck. And not for any suggestion.

Samuel12_1980

Better to be above the dashed line Good-luck

Samuel12_1980

Support at Fibo line. Good-luck

Samuel12_1980

But if not, Check out the Fibo below. The most important support for up continuance is 340$. Good-luck

Samuel12_1980

Good - luck Merry Christmas to all.

Samuel12_1980

Hope.

Samuel12_1980

I hope the company will report a good revenue with it's discount programs and black-Friday success. Merry Christmas to all.

Samuel12_1980

Hope for breaking the above red-line Good-luck

Samuel12_1980

Above Fibo can be good chance for entry. Not for any suggestion, Good luck.

Samuel12_1980

That's the risk we take, and good for Short holders.

Samuel12_1980

Target is 11.9

Samuel12_1980

Good luck to shareholders

Samuel12_1980

Next challenge is visiting MA200 - touch and go. Good luck

Samuel12_1980

ABOVE MA200, and looking good .

Samuel12_1980

only above 34.3 support at 32.64

Samuel12_1980 Updated 

I wish for upside trend line break. case of breaking, 7.15-7.1 is the first resistance. Good-luck and Shabbat shalom :)